Overview

"Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Drug B10-FC After Single Administration to Adult Patients".

Status:
NOT_YET_RECRUITING

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

A two-stage open-label, prospective, safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity study with participation of healthy volunteers in three dose-escalation groups and patients with a confirmed diagnosis of COVID-19.

Phase:

PHASE1

Details

Lead Sponsor:

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation